Leadership & Pay ·
Larimar Therapeutics appoints John B. Harlow as President and COO with $560K base salary
LRMRLarimar Therapeutics, Inc.
Larimar Therapeutics appointed John B. Harlow as President and Chief Operating Officer effective September 29, 2026. Mr. Harlow brings prior commercial leadership experience from Esperion Therapeutics, Melinta Therapeutics, and Baudax Bio. His compensation includes a $560,000 annual base salary, a $35,000 signing bonus, and a target annual bonus equal to 40% of his base salary. The company granted him an option to purchase 800,000 shares and restricted stock units for 50,000 shares as inducement grants. Severance terms provide nine months of pay and benefits upon termination without cause or for good reason, extending to twelve months following a change in control. Larimar Therapeutics operates in the biopharmaceutical industry, focusing on developing treatments for rare diseases.